Abstract: Triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, an indicator of atherogenic dyslipidemia, is a predictor of cardiovascular (CV) outcomes in the general population and has been correlated with atherosclerotic events. Whether the TG/HDL-C ratio can predict CV outcomes and survival in dialysis patients is unknown.

We performed this prospective, observational cohort study and enrolled 602 dialysis patients (539 hemodialysis and 63 peritoneal dialysis) from a single center in Taiwan followed up for a median of 3.9 years. The outcomes were the occurrence of CV events, CV death, and all-cause mortality during follow-up. The association of baseline TG/HDL-C ratio with outcomes was explored with Cox regression models, which were adjusted for demographic parameters and inflammatory/nutritional markers.

Overall, 203 of the patients experienced CV events and 169 patients died, of whom 104 died due to CV events. Two hundred fifty-four patients reached the composite CV outcome. Patients with higher TG/HDL-C levels (quintile 5) had a higher incidence of CV events (adjusted hazard ratio [HR] 2.03, 95% confidence interval [CI] 1.19–3.47), CV mortality (adjusted HR 1.91, 95% CI 1.07–3.99), composite CV outcome (adjusted HR 2.2, 95% CI 1.37–3.55), and all-cause mortality (adjusted HR 1.94, 95% CI 1.1–3.39) compared with the patients in quintile 1. However, in diabetic dialysis patients, the TG/HDL-C ratio did not predict the outcomes.

The TG/HDL-C ratio is a reliable and easily accessible predictor to evaluate CV outcomes and survival in prevalent nondiabetic dialysis patients.

ClinicalTrials.gov: NCT01457625

INTRODUCTION

Atherogenic dyslipidemia combined with high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) levels have been reported to strongly predict cardiovascular (CV) morbidity, and especially coronary artery disease in the general population. In addition, to subjects with stroke or transient ischemic attack, the presence of atherogenic dyslipidemia predicts the occurrence of CV events even if they are under adequate 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) therapy. Several investigations performed on the general population have also shown a correlation between the TG to HDL-C (TG/HDL-C) ratio and the concentration of low-density lipoprotein cholesterol (LDL-C) type B, severity of insulin resistance, and coronary atherosclerotic lesions. The TG/HDL-C ratio has been shown to precisely predict the occurrence of myocardial infarction, ischemic heart disease, and CV mortality, both in women with coronary artery disease and in the general population. Therefore, in the era of aggressive LDL-C reduction with statins, scientific evidence implicates low HDL-C and high TG as the residual CV risk observed after LDL-C has been lowered. Several landmark trials attempted to modulate the TG/HDL-C ratio in dyslipidemic patients by using fenofibrate, torcetrapib, or niacin; however, they did not clearly reduce the risk of CV events.

In patients with chronic kidney disease (CKD), LDL-C is not a good marker to assess the risk of CV events owing to its weak association with coronary events in CKD patients with a low estimated glomerular filtration rate. In addition, in trials performed in dialysis patients, no CV benefits have been clearly demonstrated with aggressive LDL-C reduction strategies. Interestingly, hypertriglyceridemia, the dominant dyslipidemia in CKD patients, has been reported to be an inverse predictor of mortality in nondialyzed CKD patients but to have a U-shaped relationship with mortality in hemodialysis (HD) patients. In contrast, HDL-C has been reported to have a discordant association with all-cause or...
CV mortality in HD patients. Whether the TG/HDL-C ratio is a potential or an even better predictor of CV outcomes in dialysis patients remains unknown because of the limited amount of data on the prognostic utility of the TG/HDL-C ratio in this population. Therefore, we initiated this prospective, observational study to determine whether the TG/HDL-C ratio can predict CV events and CV mortality in prevalent dialysis patients.

MATERIALS AND METHODS

Subjects
This was a prospective study performed using 3 pooled patient cohorts. The first cohort was composed of 370 prevalent HD patients, the second cohort was composed of 238 prevalent HD patients, and the third cohort was composed of 220 HD patients and 63 peritoneal dialysis (PD) patients. These patient cohorts have been described previously in more detail. In brief, the 3 cohorts were collected prospectively and intentionally to investigate the associations among serum high-sensitivity C-reactive protein (hs-CRP), fetuin A, inflammatory markers, and visceral adiposity with specific outcomes (such as arteriovenous access patency and CV events) in prevalent dialysis patients at the Far Eastern Memorial Hospital (FEMH) from 2007 to 2011. In the 3 cohorts, the patients with available data on TG and HDL-C levels were included in the analysis, and the exclusion criteria for all 3 cohorts were as follows: active infection, recent hospitalization within 3 months, psychotic illness or other communication problem, active malignancy, or other dialysis facilities and were no longer followed up, whichever came first.

Follow-up was started from February 2007 (first cohort entry), March 2009 (second cohort entry), or March 2011 (third cohort entry) and censored on the date of the first CV event, at the end of the study (July 1, 2014), on the date of death or renal transplantation, or at the time the patients were transferred to other dialysis facilities and were no longer followed up, whichever came first.

Statistical Analysis
Continuous data were presented as mean ± SD or median (interquartile range), and categorical data were reported as percentages. Differences in baseline characteristics and biochemical parameters between the HD and PD patients were compared using the Student t test and Mann–Whitney U test. Comparisons of the patients in different quintiles of TG/HDL-C ratio were performed by analysis of variance for continuous variables and the nonparametric Kruskal–Wallis test for non-normally distributed continuous variables. The χ2 test was used for categorical variables.

Outcome analysis was performed using Cox proportional hazard models. We used the “Enter” method to analyze the hazard ratio (HR) of each primary predictor variable in the model. Because the TG/HDL-C ratio was not normally distributed in the dialysis patients, we constructed plots of the TG/HDL-C ratios and HRs of the outcomes using the Lowess function. The results revealed a nonlinear relationship, suggesting the need for stratification of the patients into quintiles according to their TG/HDL-C ratio for outcome analysis. Therefore, we stratified the patients into quintiles according to their TG/HDL-C ratio. The primary predictor variable was the TG/HDL-C ratio in each quintile. We also selected non-HDL-C (defined as T-CHO minus HDL-C) and TG/HDL-C ratio >3.8 as primary predictors according to published data. Similarly, because non-HDL-C was also not normally distributed, we reconstructed plots of non-HDL-C and HRs of the outcomes using the Lowess function and stratified the patients into tertiles accordingly for analysis.

The modification effects of nutritional status, inflammatory status, and diabetic status on the relationship between primary predictor variables and outcomes were also evaluated in predefined subgroups, which were defined according to the median values of GNRI and hs-CRP, or based on the patient’s medical condition (presence of diabetes mellitus [DM]).

The nutritional status of the participants was quantified using the geriatric nutritional risk index (GNRI), which was calculated based on serum albumin level and body weight as follows: GNRI = [14.89 × albumin level (g/dL)] + [41.7 × body weight/WLo], where WLo is the ideal body weight calculated from the Lorentz equation. The GNRI has previously been validated in dialysis patients, and a higher GNRI indicates better nutritional status. The hs-CRP levels were determined using the immunonephelometric method using a Tina-quant CRP (Latex) ultrasensitive assay (D & P Modular Analyzer; Roche Diagnostics GmbH, Mannheim, Germany).

Outcomes
The primary outcomes were CV events and CV mortality, considered either separately or jointly (composite CV outcome). CV events were defined as the new occurrence of CV events, including coronary events (nonfatal myocardial infarction, unstable angina, and coronary revascularization), hospitalized heart failure, hospitalized incident stroke (either ischemic or hemorrhagic stroke), and incident peripheral arterial occlusion disease requiring surgical intervention. CV mortality was defined as death caused by the CV events defined above. The secondary outcome was defined as all-cause mortality. The outcome information was centrally adjudicated, in accordance with prespecified definitions, by trained clinicians and nephrologists.
adjusted covariates included age, sex, dialysis vintage, dialysis modality, patient cohorts, presence of DM and hypertension, concurrent CV disease, GNRI, hs-CRP and calcium phosphate product (CaxP) levels in the analysis of a CV event, composite outcome, and all-cause mortality. To further evaluate and compare the predictive performance of the TG/HDL-C ratio and non-HDL-C, we used receiver operating characteristic (ROC) curves for censored data and the area under the ROC curve (AUC) as the criterion. All of the statistical analyses were performed using SPSS version 19.0 software (SPSS, Inc, Chicago, IL). A P value <0.05 was considered to be statistically significant.

RESULTS

Baseline Characteristics of the Participants

The baseline characteristics of all of the participants, the participants receiving HD or PD and participants in the TG/HDL-C quintiles are summarized in Tables 1 and 2. In general, the patients receiving PD were younger, had a lower percentage of diabetes, lower albumin levels, and higher T-CHO and LDL-C levels. However, similar levels of TG, HDL-C, TG/ HDL-C ratio, and GNRI were found in the patients undergoing either HD or PD (Table 1). Overall, the patients in the TG/HDL-C quintiles had different percentages of diabetes, lipid profiles, hs-CRP level, and nutritional status (Table 2).

Outcomes

Overall, 203 of the participants experienced CV events, and 169 patients died, of whom 104 died due to CV events. Two hundred fifty-four patients reached the composite CV outcome. Of the 203 patients with CV events, 67 had intracranial hemorrhage or ischemic stroke, 106 had coronary artery disease (either nonfatal acute myocardial infarction or coronary revascularization/coronary bypass surgery), 24 had peripheral arterial occlusion disease, and 6 were hospitalized for heart failure. Of the 104 patients with CV death, 45 were due to coronary artery disease, 37 sudden cardiac death, 18 cerebrovascular events, and 4 were defined as arrhythmia. The median follow-up period was 3.9 years (range 0.2–7.4 years).

| TABLE 1. Baseline Characteristics of All Patients and the Patients Undergoing HD and PD |
| --- |
| **Age, y** | **n = 602** | **HD Patients n = 539** | **PD Patients n = 63** | **P Value** |
| 59 ± 12 | 62 ± 11 | 57 ± 12 | <0.001 |
| Female sex, % | 50 | 49 | 65 | 0.01 |
| DM, % | 50 | 52 | 30 | 0.01 |
| Dialysis vintage, y | 3.6 ± 3.6 | 3.8 ± 3.5 | 3.4 ± 3.1 | 0.3 |
| History of hypertension, % | 78 | 78 | 83 | 0.3 |
| History of previous CVD, % | 24 | 23 | 30 | 0.3 |
| Systolic BP, mm Hg | 146 ± 31 | 146 ± 44 | 147 ± 70 | 0.1 |
| Diastolic BP, mm Hg | 84 ± 13 | 86 ± 19 | 83 ± 14 | 0.2 |
| BMI, kg/m² | 22.7 ± 3.6 | 22.7 ± 4.0 | 23.7 ± 3.2 | 0.2 |
| Laboratory data |
| Hemoglobin, g/dL | 11.0 ± 1.5 | 11.0 ± 1.5 | 10.4 ± 1.5 | 0.02 |
| Cre, mg/dL | 10.5 (9.0, 11.9) | 10.5 (9.0, 11.8) | 11.3 (9.3, 14.7) | 0.003 |
| K, mmol/L | 4.8 ± 0.8 | 4.8 ± 0.8 | 4.1 ± 0.8 | <0.001 |
| Ca, mg/dL; corrected | 9.3 (8.8, 9.6) | 9.3 (8.8, 9.6) | 9.3 (8.9, 9.7) | 0.5 |
| P, mg/dL | 5.1 (4.3, 6.1) | 5.1 (4.2, 6.2) | 5.1 (4.6, 5.7) | 0.7 |
| CaxP | 47 (39–57) | 47 (39, 58) | 47 (42, 54) | 0.7 |
| iPTH, pg/mL | 241 (119–446) | 238 (118, 439) | 291 (138, 531) | 0.4 |
| hs-CRP, mg/L | 3.3 (1.2–8.3) | 3.5 (1.3, 8.4) | 2.2 (0.7, 6.9) | 0.07 |
| Albumin, g/L | 4.1 ± 0.4 | 4.1 ± 0.4 | 3.9 ± 0.3 | <0.001 |
| T-CHO, mg/dL | 173 (147, 203) | 171 (145,201) | 194 (164,223) | <0.001 |
| TG, mg/dL | 135 (90, 215) | 142 (93, 215) | 122 (74, 224) | 0.2 |
| HDL-C, mg/dL | 44 (36, 55) | 45 (36, 56) | 42 (35, 55) | 0.5 |
| LDL-C, mg/dL | 93 (69, 118) | 91 (67, 116) | 118 (89, 138) | <0.001 |
| TG/HDL-C ratio | 3.14 (1.79, 5.66) | 3.15 (1.8, 5.66) | 2.98 (1.61, 5.97) | 0.8 |
| GNRI | 102.9 (96.7, 109.9) | 103.3 (96.6, 110.1) | 101.3 (97.3, 108.3) | 0.3 |
| Medications, % |
| ESA | 91 | 91 | 90 | 0.3 |
| HMG-CoA reductase inhibitors | 22 | 25 | 21 | 0.5 |
| Antihypertensive agents | 55 | 60 | 52 | 0.2 |

Conversion factors for units: hemoglobin in g/dL to g/L, ×10; serum calcium in mg/dL to mmol/L, ×0.2495; serum phosphate in mg/dL to mmol/L, ×0.3229; serum T-CHO in mg/dL to mmol/L, ×0.02586; serum LDL-C in mg/dL to mmol/L, ×0.02586; serum TG in mg/dL to mmol/L, ×0.01129; serum albumin in g/dL to g/L, ×10. No conversion is necessary for serum iPTH in pg/mL and mg/L; serum potassium in mEq/L and mmol/L. BMI = body mass index, BP = blood pressure, CaxP = calcium phosphate product, Cre = creatinine, CVD = cardiovascular disease, DM = diabetes mellitus, ESA = erythropoiesis-stimulating agents, GNRI = geriatric nutritional risk index, HD = hemodialysis, HDL-C = high-density lipoprotein cholesterol, HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A, hs-CRP = high-sensitivity C-reactive protein, iPTH = intact parathyroid hormone, LDL-C = low-density lipoprotein cholesterol, T-CHO = total cholesterol, TG = triglyceride, TG/HDL-C = triglyceride to high-density lipoprotein cholesterol ratio, PD = peritoneal dialysis.
## TABLE 2. Baseline Characteristics of the Patients by TG/HDL-C Quintiles

| Quintile | TG/HDL-C Ratio | Laboratory data | Medications, % | Age, y | Female sex, % | DM, % | Dialysis vintage, y | History of hypertension, % | History of previous CVD, % | Systolic BP, mm Hg | Diastolic BP, mm Hg | BMI, kg/m² | TG/HDL-C ratio | LDL-C, mg/dL | HDL-C, mg/dL | T-CHO, mg/dL | hs-CRP, mg/L | CaxP | Albumin, g/L | Antihypertensive agents |
|-----------|----------------|-----------------|----------------|-------|---------------|------|-------------------|-----------------------------|---------------------------|----------------|----------------|-----------|---------------|-------------|-------------|-------------|-------------|------|-------------|----------------------------|
| 1 (0.38–1.55) | 2.05 (1.79, 2.27) | 11.0 ± 1.4 | 50 | 60 ± 13 | 55 | 27 | 2.8 (1.8, 4.6) | 73 | 18 | 146 ± 44 | 13 ± 86 | 67 | 66 | 20.3 ± 3.9 | 4.9 | 5.3 | 91 |
| 2 (1.56–2.52) | 3.14 (2.89, 3.58) | 11.0 ± 1.6 | 50 | 60 ± 13 | 55 | 27 | 2.4 (1.4, 4.4) | 76 | 18 | 147 ± 70 | 14 ± 86 | 67 | 66 | 22.0 ± 3.3 | 4.7 | 4.7 | 91 |
| 3 (2.55–4.07) | 5.09 (4.63, 5.85) | 11.0 ± 1.5 | 50 | 60 ± 13 | 55 | 27 | 2.1 (1.4, 4.2) | 78 | 18 | 148 ± 60 | 13 ± 86 | 67 | 66 | 22.8 ± 3.2 | 4.7 | 4.7 | 91 |
| 4 (4.08–6.6) | 7.09 (6.35, 7.85) | 11.0 ± 1.7 | 50 | 60 ± 13 | 55 | 27 | 2.4 (1.4, 4.0) | 82 | 18 | 149 ± 80 | 13 ± 86 | 67 | 66 | 23.4 ± 3.8 | 4.8 | 4.8 | 91 |
| 5 (>6.6) | 9.09 (8.35, 9.85) | 11.0 ± 1.5 | 50 | 60 ± 13 | 55 | 27 | 2.4 (1.5, 4.5) | 83 | 18 | 148 ± 80 | 13 ± 86 | 67 | 66 | 25.6 ± 3.7 | 4.9 | 4.9 | 91 |

**Conversion factors for units:** hemoglobin in g/dL to g/L, serum albumin in g/dL to g/L, serum calcium in mg/dL to mmol/L, serum creatinine in mg/dL to mmol/L, serum potassium in mEq/L to mmol/L, BMI = body mass index, BP = blood pressure, CaxP = calcium phosphate product, Cre = creatinine, CVD = cardiovascular disease, DM = diabetes mellitus, ESA = erythropoiesis-stimulating agents, GNRI = geriatric nutritional risk index, HDL-C = high-density lipoprotein cholesterol, HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A, hs-CRP = high-sensitivity C-reactive protein, iPTH = intact parathyroid hormone, LDL-C = low-density lipoprotein cholesterol, T-CHO = total cholesterol, TG/HDL-C = triglyceride to high-density lipoprotein cholesterol ratio, TG = triglyceride.

### Associations Between TG/HDL-C Ratio, Lipid Profiles, and Outcomes

In the multivariate Cox regression model, the patients with a higher TG/HDL-C level quintile 5 had a higher incidence of CV events (adjusted HR 2.03, 95% confidence interval [CI] 1.19–3.47), CV mortality (adjusted HR 1.91, 95% CI 1.07–3.99), composite CV outcome (adjusted HR 2.2, 95% CI 1.37–3.55), and all-cause mortality (adjusted HR 1.94, 95% CI 1.11–3.39) compared with the patients in quintile 1. Taking TG/HDL-C ratio >3.8 as a dichotomous variable, the patients with a TG/HDL-C ratio >3.8 had a higher incidence of composite CV outcome. Similarly, the patients in non-HDL-C tertile 3 also had a higher incidence of CV events, CV mortality, and composite CV outcome compared with the patients in non-HDL-C tertile 1 (Table 3). Neither HDL-C nor TG level predicted all outcomes (all P > 0.05).

The HRs of the 4 outcomes of the patients by respective quintile of TG/HDL-C ratio are shown in Table 3. As the TG/HDL-C level increased, the HRs of the composite CV outcomes also gradually increased (P for trend = 0.001), and there was an identical trend for the HRs of all-cause mortality (P for trend = 0.02). In addition, as the TG/HDL-C level increased, the HRs of CV events and CV mortality also gradually increased (P for trend = 0.007 and 0.04, respectively). In contrast, as the non-HDL-C level increased, the HRs of CV events, CV mortality, composite CV outcome, and all-cause mortality did not increase accordingly (P for trend = 0.09, 0.1, 0.08, and 0.4, respectively).

### Effect Modification of Prespecified Subgroups on the Relationship Between TG/HDL-C Ratio and Outcomes

The predictive power of the TG/HDL-C ratio on the composite CV outcomes and all-cause mortality was consistent in all of the prespecified subgroups, regardless of their inflammatory condition (hs-CRP level) and nutritional status (GNRI).
level), except for DM status. We found an interaction between TG/HDL-C ratio and DM status in the prediction of the composite CV outcomes ($P = 0.04$, for interaction). As shown in Figure 1, in the patients without DM, the TG/HDL-C ratio had a significant association with the HRs of the composite CV outcomes; however, this association did not exist in the DM patients. In the Cox regression model, only nondiabetic patients with higher TG/HDL-C levels had a higher incidence of the composite CV outcome ($P$ for trend $= 0.03$, adjusted HR $2.91$, 95% CI $1.35–6.26$, quintile 5 vs quintile 1) and CV events ($P$ for trend $= 0.007$, adjusted HR $3.69$, 95% CI $1.63–8.38$, quintile 5 vs quintile 1).

**ROC Analysis of the TG/HDL-C Ratio and Non-HDL-C Level as Predictors of the Outcomes**

The AUC for the TG/HDL-C ratio and non-HDL-C level versus outcomes are shown in Figure 2. The TG/HDL-C ratio and non-HDL-C levels had a similar predictive performance for CV outcome and CV death; however, the TG/HDL-C ratio had a superior predictive performance for composite CV outcome ($AUC = 60.0, 95\% CI 55.4–64.0$ vs $AUC = 52.8, 95\% CI 55.2–48.2, P = 0.01$ by DeLong test) and all-cause mortality ($AUC = 55.3, 95\% CI 52.7–61.0$ vs $AUC = 47.7, 95\% CI 52.5–42.6, P = 0.02$ by DeLong test).

**DISCUSSION**

The main finding of this study is that the baseline TG/HDL-C ratio was predictive of composite CV outcomes and all-cause mortality in prevalent dialysis patients regardless of nutritional or inflammatory status. In addition, it had a noteworthy interaction with DM status when assessing the prediction of outcomes. Atherogenic dyslipidemia in dialysis patients with the TG/HDL-C ratio for stratification of its severity should be recognized as a crucial and easily available tool to predict long-term CV outcomes and survival.

Dialysis patients have unique lipid profiles, and the association between lipid profiles and CV outcomes and survival are completely different from those in the general population. In several landmark studies, dialysis patients have been reported to have unique correlations between levels of T-CHO and LDL-C,

![FIGURE 1. Association between the adjusted HRs of the composite CV outcomes (with log-transformation) and the TG/HDL-C ratio in dialysis patients with or without diabetes. In the diabetic dialysis patients, the TG/HDL-C ratio did not have an association with the composite outcome. CV = cardiovascular, DM = diabetes mellitus, HDL-C = high-density lipoprotein cholesterol, HR = hazard ratio, TG = triglyceride.](image)

| Variables | CV Event Adjusted HR (95% CI) | CV Mortality Adjusted HR (95% CI) | Composite CV Outcome Adjusted HR (95% CI) | All-Cause Mortality Adjusted HR (95% CI) |
|-----------|-------------------------------|----------------------------------|------------------------------------------|------------------------------------------|
| TG/HDL-C ratio |                               |                                  |                                          |                                          |
| TG/HDL-C ratio quintiles (fifth vs first quintile) | 2.03 (1.19–3.47) | 1.91 (1.07–3.99) | 2.20 (1.37–3.55) | 1.94 (1.10–3.39) |
| TG/HDL-C ratio quintiles (fourth vs first quintile) | 1.45 (0.9–2.44) | 1.35 (0.99–2.18) | 1.99 (1.0–2.32) | 1.06 (0.71–1.85) |
| TG/HDL-C ratio quintiles (third vs first quintile) | 2.01 (1.1–3.8) | 1.32 (0.82–3.21) | 2.12 (1.4–3.5) | 1.53 (0.91–2.59) |
| TG/HDL-C ratio quintiles (second vs first quintile) | 1.31 (0.78–2.21) | 1.00 (0.47–1.95) | 1.31 (0.83–2.09) | 0.86 (0.91–2.59) |
| TG/HDL-C ratio >3.8 (yes vs no) | 1.24 (0.91–1.68) | 1.16 (0.77–1.74) | 1.26 (1.00–1.65) | 1.23 (0.89–1.69) |
| Non-HDL-C |                               |                                  |                                          |                                          |
| Non-HDL-C (third vs first tertile) | 1.51 (1.02–2.21) | 1.73 (1.01–2.97) | 1.48 (1.05–2.08) | 1.35 (0.89–2.06) |
| Non-HDL-C (second vs first tertile) | 1.39 (0.96–2.0) | 1.22 (0.74–2.01) | 1.26 (0.9–1.74) | 1.12 (0.76–1.64) |

CaxP = calcium phosphate product, CI = confidence interval, CV = cardiovascular, DM = diabetes mellitus, GNRI = geriatric nutritional risk index, HDL-C = high-density lipoprotein cholesterol, HR = hazard ratio, hs-CRP = high-sensitivity C-reactive protein, non-HDL-C = non-high-density lipoprotein cholesterol, TG = triglyceride, TG/HDL-C = triglyceride to high-density lipoprotein cholesterol ratio.

*Adjusted for sex, age; dialysis vintage; presence of DM, hypertension, and concurrent CV disease; patient cohort; dialysis modality; GNRI, CaxP, and hs-CRP levels.
predict CV outcomes in dialysis patients, as it has already been
The TG/HDL-C ratio may therefore be an optimal marker to
strate the predictive ability of the TG/HDL-C ratio for CV
to the best of our knowledge, this is the first study to demon-
results clearly demonstrated their predictive power (Table 3).
To the best of our knowledge, this is the first study to demon-
strate the predictive ability of the TG/HDL-C ratio for CV
outcomes and survival in patients undergoing prevalent dialysis.
The TG/HDL-C ratio may therefore be an optimal marker to
predict CV outcomes in dialysis patients, as it has already been
utilized in the general population. In our results, a TG/
HDL-C ratio > 3.8 also predicted the occurrence of composite
CV events, which could be partially explained by reports that a
TG/HDL-C ratio > 3.8 is a strong indicator of the presence of
atherogenic small LDLs. In other words, a higher TG/HDL-C
ratio indicates a milieu with abundant atherogenic lipoprotein
particles resulting in consequent CV complications not only in
the general population but also in dialysis patients. In addition,
the non-HDL-C level predicted the occurrence of CV events,
which is consistent with the results of previous studies.

In women at high risk of CV events, the TG/HDL-C ratio
was a powerful predictor of coronary artery disease and all-
cause mortality, with an approximately 2-fold increase after 6
years of follow-up. Furthermore, other studies have shown
modest to strong effect sizes (adjusted HR from 2 to 16) in the
prediction of CV events and mortality. In our results, the
effect size of the TG/HDL-C ratio in the prediction of composite
CV outcome was moderate (adjusted HR 2.2, Table 3); how-
ever, the effect sizes were attenuated in CV and all-cause
mortality (Table 3). A possible explanation is that malnutri-
tion—inflammation complex syndrome interacts with athero-
genic lipoprotein particles in dialysis patients; however, effec-
tions of the TG/HDL-C ratio quintiles (Table 2). This finding
is consistent with that in the general population, and it has been
reported that patients with a high TG/HDL-C ratio are predis-
posed to have metabolic syndrome or consequent DM. In
other words, the patients with a high TG/HDL-C ratio, meta-
bolic syndrome, and DM may be considered to have a metabolic
continuum, of which diabetes is the end stage. In patients with
both DM and atherogenic dyslipidemia, diabetic status is crucial
when assessing CV outcomes compared with atherogenic dys-
lipidemia. As shown in landmark trials, the manipulation
of high TG and low HDL-C levels in DM patients with medical
interventions does not reduce the risk of CV outcomes. Con-
sequently, the utility of the TG/HDL-C ratio for the prediction
of long-term CV outcomes in diabetic dialysis patients should
be carefully explored in further large-scale investigations.

The strengths of this study are its prospective nature and
full adjustment for multiple CV and survival predictors, espe-
cially inflammatory (hs-CRP) and nutritional (GNRI) factors, in
the outcome analysis. However, there are some limitations to
this study. First, the observational nature of this study pre-
cludes the conclusions of a causal relationship. Second, we did
not check the specific lipoproteins related to atherogenic dyslipidemia such as apolipoprotein B, which may be more
specific to LDL particles. In addition, the relationship between
TG/HDL-C ratio and apolipoproteins in dialysis patients needs
to be validated further. Third, this was a single-center study,
and all of the participants were treated by the same physicians
and underwent uniform laboratory measurements during the
observation period, which guaranteed the accuracy of our
results. However, our conclusions cannot be generalized to
other ethnicities.

In summary, our results suggest that the TG/HDL-C ratio
can independently predict composite CV outcomes and
mortality in prevalent dialysis patients, especially nondiabetic
dialysis patients.

FIGURE 2. ROC curve of the TG/HDL-C ratio and non-HDL-C level as predictors of the outcomes. The TG/HDL-C ratio had a superior
predictive performance for composite CV outcome and all-cause mortality (P = 0.01 and 0.02, respectively, by DeLong test). CV =
cardiovascular, HDL-C = high-density lipoprotein cholesterol, ROC = receiver operating characteristic, TG = triglyceride.

and CV outcomes, which is known as the “cholesterol para-
doxx,” In addition, recent published data have shown the
lack of an association between HDL-C levels and the risk of CV
events in diabetic HD patients, and in a large HD cohort who
were followed up for 3 years, HDL-C and TG did not predict CV
or all-cause mortality in HD patients. In the current study, we
used the TG/HDL-C ratio to evaluate long-term CV composite
outcomes and survival in both HD and PD patients, and the
results clearly demonstrated their predictive power (Table 3).
To the best of our knowledge, this is the first study to demon-
strate the predictive ability of the TG/HDL-C ratio for CV
outcomes and survival in patients undergoing prevalent dialysis.

REFERENCES

1. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. *Circulation*. 2001;104:3046–3051.

2. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. *Circulation*. 1992;85:37–45.

3. Sirimargo C, Labrecque J, Bruckert E, et al. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. *Stroke*. 2014;45:1429–1436.

4. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. *Clin Chem*. 2003;49:1873–1880.

5. Hanak V, Munoz J, Teague J, et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. *Am J Cardiol*. 2004;94:219–222.

6. McLaughlin T, Reaven G, Abbasi F, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? *Am J Cardiol*. 2005;96:399–404.

7. Gaziano JM, Hennekens CH, O’Donnell CJ, et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. *Circulation*. 1997;96:2520–2525.

8. Jeppesen J, Hein HO, Suadcani P, et al. Low triglycerides-high density lipoprotein cholesterol and risk of ischemic heart disease. *Arch Intern Med*. 2001;161:361–366.

9. Barzi F, Patel A, Woodward M, et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. *Ann Epidemiol*. 2005;15:405–413.

10. Brttnner T, Johnson BD, Zineh I, et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women’s Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2009;157:548–555.

11. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357:2109–2122.

12. Group AS, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*. 2010;362:1563–1574.

13. Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2003;362:1563–1574.

14. Tonelli M, Muntner P, Lloyd A, et al. Association between LDL-C and the triglyceride/hDL-C ratio predicts atherosclerotic cardiovascular events in hemodialysis patients. *Kidney Int*. 2009;77:765–772.

15. Moradi H, Streja E, Kashyap ML, et al. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. *Nephrol Dial Transplant*. 2014;29:1554–1562.

16. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition–inflammation–cachexia syndrome. *Am J Kidney Dis*. 2002;39:745–755.

17. Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. *J Am Soc Nephrol*. 2007;18:293–303.

18. Postorino M, Marino C, Tripepi G, et al. Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. *Kidney Int*. 2011;79:765–772.

19. Postorino M, Marino C, Tripepi G, et al. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. *Nephrol Dial Transplant*. 2014;29:484–492.

20. Chen HY, Chiu YL, Chang YF, et al. Association of low serum fetuin A levels with poor arteriovenous access patency in patients undergoing maintenance hemodialysis. *Am J Kidney Dis*. 2010;56:720–727.

21. Chen HY, Chiu YL, Hsu SP, et al. Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients. *Eur J Endocrinol*. 2009;161:777–783.

22. Chiu YL, Chen HY, Chuang YF, et al. Association of hyperlipidemia with atherosclerotic cardiovascular disease and optimally treated patients at high risk for coronary events. *Nephrol Dial Transplant*. 2008;23:3685–3689.

23. Yamada K, Furuya R, Takita T, et al. Simplified nutritional screening tools for patients on maintenance hemodialysis. *Am J Clin Nutr*. 2008;87:106–113.

24. Shoji T, Masakane I, Watanabe Y, et al. Committee of Renal Data Registry JSIDT. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. *Clin J Am Soc Nephrol*. 2011;6:1112–1120.

25. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. *JAMA*. 2004;291:451–459.

26. Sultman ME, Stenvinkel P, Barany P, et al. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hyperhomocysteinemia, malnutrition, inflammation, and diabetes mellitus. *Am J Kidney Dis*. 2003;41(3 Suppl 1):S89–95.

27. Nishizawa Y, Shoji T, Kikiyama R, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. *Kidney Int Suppl*. 2003;84:S171–S120.

28. Qureshi AR, Alvesstrad A, Divino-Filho JC, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. *J Am Soc Nephrol*. 2002;13(Suppl 1):S28–S36.

29. Levey SF, Strandwerth RL, Jones CA, et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. *Am J Kidney Dis*. 1998;31:997–1006.

30. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. *J Am Soc Nephrol*. 2001;12:2131–2138.

31. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. *Am Heart J*. 2011;161:538–543.

32. Kech A, Simes JR, Barber P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005;366:1849–1861.